Oppenheimer Reiterates Hold Rating for Teva Pharmaceutical Industries (TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA)‘s stock had its “hold” rating restated by equities researchers at Oppenheimer in a research note issued on Wednesday. Oppenheimer also issued estimates for Teva Pharmaceutical Industries’ Q3 2018 earnings at $0.49 EPS and FY2018 earnings at $2.66 EPS.

A number of other equities research analysts have also recently weighed in on the stock. Credit Suisse Group set a $26.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Sunday, October 14th. Goldman Sachs Group upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “conviction-buy” rating and set a $30.00 price target for the company in a research report on Monday, October 1st. Leerink Swann upgraded shares of Teva Pharmaceutical Industries from an “underperform” rating to a “market perform” rating and lifted their price target for the company from $16.00 to $24.00 in a research report on Monday, October 1st. Wells Fargo & Co set a $23.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Thursday, September 27th. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $25.00 price objective on shares of Teva Pharmaceutical Industries in a report on Thursday, September 27th. Five analysts have rated the stock with a sell rating, sixteen have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $21.68.

Shares of TEVA opened at $21.27 on Wednesday. Teva Pharmaceutical Industries has a 1-year low of $10.85 and a 1-year high of $25.96. The stock has a market cap of $21.55 billion, a price-to-earnings ratio of 5.41, a P/E/G ratio of 1.75 and a beta of 0.71. The company has a quick ratio of 0.69, a current ratio of 1.03 and a debt-to-equity ratio of 1.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Thursday, August 2nd. The company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.14. Teva Pharmaceutical Industries had a negative net margin of 47.98% and a positive return on equity of 19.92%. The business had revenue of $4.70 billion during the quarter, compared to analysts’ expectations of $4.75 billion. During the same period last year, the business earned $1.02 earnings per share. The business’s revenue for the quarter was down 17.8% on a year-over-year basis. As a group, equities research analysts predict that Teva Pharmaceutical Industries will post 2.69 earnings per share for the current fiscal year.

In other news, EVP Sven Dethlefs purchased 2,000 shares of the firm’s stock in a transaction that occurred on Friday, August 3rd. The stock was bought at an average price of $21.92 per share, for a total transaction of $43,840.00. Following the completion of the purchase, the executive vice president now directly owns 6,445 shares of the company’s stock, valued at $141,274.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Richard Daniell sold 2,488 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, September 18th. The stock was sold at an average price of $23.69, for a total transaction of $58,940.72. Following the completion of the transaction, the vice president now owns 2,488 shares of the company’s stock, valued at approximately $58,940.72. The disclosure for this sale can be found here. Insiders sold 10,350 shares of company stock valued at $239,430 in the last quarter. 0.43% of the stock is owned by insiders.

A number of institutional investors have recently modified their holdings of TEVA. Wealthstreet Investment Advisors LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $200,000. MAI Capital Management purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $204,000. Greenleaf Trust purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $215,000. Rehmann Capital Advisory Group lifted its position in shares of Teva Pharmaceutical Industries by 136.2% during the 2nd quarter. Rehmann Capital Advisory Group now owns 9,019 shares of the company’s stock worth $219,000 after buying an additional 5,201 shares during the last quarter. Finally, Court Place Advisors LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $220,000. Institutional investors own 64.65% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Story: How much money do you need to begin day trading?

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply